Immunological off-target effects of imatinib | Nature Reviews Clinical Oncology
Journal of Biomedical and Pharmaceutical Research
Frontiers | Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
Journal of Biomedical and Pharmaceutical Research
What is Gleevec? - Quora
Figure 1 from Quantification of an anti-cancer drug ( imatinib ) in human plasma | Semantic Scholar
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
Imatinib (Gleevec) - Oncology Nurse Advisor
Mechanism of action of imatinib mesylate (Gleevec ® ). Imatinib... | Download Scientific Diagram
Imatinib - an overview | ScienceDirect Topics
Nilotinib Pathway, Pharmacokinetics/Pharmacodynamics
Defining molecular mechanisms of imatinib treatment in GIST - The Life Raft Group
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy | Journal of Hematology & Oncology | Full Text
Modern Therapy of Chronic Myeloid Leukemia | IntechOpen
Is there a cloud in the silver lining for imatinib? | British Journal of Cancer
Imatinib - an overview | ScienceDirect Topics
Mechanism of action of imatinib | Biomed Graphics
Figure 2, Schematic model for the mechanism of action of Gleevec (imatinib) - Mechanistic Evidence in Evidence-Based Medicine: A Conceptual Framework - NCBI Bookshelf
Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update - Cytotherapy
Defining molecular mechanisms of imatinib treatment in GIST - The Life Raft Group
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
FDA licences imatinib mesylate for CML - The Lancet Oncology
Gleevec: Mechanism of Action - YouTube
File:Mechanism imatinib.svg - Wikimedia Commons
Mechanism of action of Imatinib; Imatinib binds to the ATP binding site... | Download Scientific Diagram
Frontiers | Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. | Australian Medical Student Journal
